351 related articles for article (PubMed ID: 7987388)
1. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.
Kamb A; Shattuck-Eidens D; Eeles R; Liu Q; Gruis NA; Ding W; Hussey C; Tran T; Miki Y; Weaver-Feldhaus J
Nat Genet; 1994 Sep; 8(1):23-6. PubMed ID: 7987388
[TBL] [Abstract][Full Text] [Related]
2. Germline p16 mutations in familial melanoma.
Hussussian CJ; Struewing JP; Goldstein AM; Higgins PA; Ally DS; Sheahan MD; Clark WH; Tucker MA; Dracopoli NC
Nat Genet; 1994 Sep; 8(1):15-21. PubMed ID: 7987387
[TBL] [Abstract][Full Text] [Related]
3. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds.
Gruis NA; van der Velden PA; Sandkuijl LA; Prins DE; Weaver-Feldhaus J; Kamb A; Bergman W; Frants RR
Nat Genet; 1995 Jul; 10(3):351-3. PubMed ID: 7670475
[TBL] [Abstract][Full Text] [Related]
4. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
Liu Q; Neuhausen S; McClure M; Frye C; Weaver-Feldhaus J; Gruis NA; Eddington K; Allalunis-Turner MJ; Skolnick MH; Fujimura FK
Oncogene; 1995 Mar; 10(6):1061-7. PubMed ID: 7700630
[TBL] [Abstract][Full Text] [Related]
5. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma.
Liu L; Lassam NJ; Slingerland JM; Bailey D; Cole D; Jenkins R; Hogg D
Oncogene; 1995 Jul; 11(2):405-12. PubMed ID: 7624155
[TBL] [Abstract][Full Text] [Related]
6. Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis.
Luca M; Xie S; Gutman M; Huang S; Bar-Eli M
Oncogene; 1995 Oct; 11(7):1399-402. PubMed ID: 7478563
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds.
Holland EA; Beaton SC; Becker TM; Grulet OM; Peters BA; Rizos H; Kefford RF; Mann GJ
Oncogene; 1995 Dec; 11(11):2289-94. PubMed ID: 8570179
[TBL] [Abstract][Full Text] [Related]
8. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
[TBL] [Abstract][Full Text] [Related]
9. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.
Ohta M; Nagai H; Shimizu M; Rasio D; Berd D; Mastrangelo M; Singh AD; Shields JA; Shields CL; Croce CM
Cancer Res; 1994 Oct; 54(20):5269-72. PubMed ID: 7923152
[TBL] [Abstract][Full Text] [Related]
10. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma.
Ohta M; Berd D; Shimizu M; Nagai H; Cotticelli M-G ; Mastrangelo M; Shields JA; Shields CL; Croce CM; Huebner K
Int J Cancer; 1996 Mar; 65(6):762-7. PubMed ID: 8631588
[TBL] [Abstract][Full Text] [Related]
11. Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines.
Pollock PM; Yu F; Qiu L; Parsons PG; Hayward NK
Oncogene; 1995 Aug; 11(4):663-8. PubMed ID: 7651729
[TBL] [Abstract][Full Text] [Related]
12. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
Pollock PM; Pearson JV; Hayward NK
Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
[TBL] [Abstract][Full Text] [Related]
13. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK
Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the molecular genetics of malignant melanoma.
Haluska FG; Housman DE
Cancer Surv; 1995; 25():277-92. PubMed ID: 8718523
[TBL] [Abstract][Full Text] [Related]
15. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.
Bahuau M; Vidaud D; Jenkins RB; Bièche I; Kimmel DW; Assouline B; Smith JS; Alderete B; Cayuela JM; Harpey JP; Caille B; Vidaud M
Cancer Res; 1998 Jun; 58(11):2298-303. PubMed ID: 9622062
[TBL] [Abstract][Full Text] [Related]
16. Novel germline p16 mutation in familial malignant melanoma in southern Sweden.
Borg A; Johannsson U; Johannsson O; Häkansson S; Westerdahl J; Mäsbäck A; Olsson H; Ingvar C
Cancer Res; 1996 Jun; 56(11):2497-500. PubMed ID: 8653684
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A/p16 is inactivated in most melanoma cell lines.
Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
[TBL] [Abstract][Full Text] [Related]
18. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
19. Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF.
Liu L; Goldstein AM; Tucker MA; Brill H; Gruis NA; Hogg D; Lassam NJ
Genes Chromosomes Cancer; 1997 May; 19(1):52-4. PubMed ID: 9135995
[TBL] [Abstract][Full Text] [Related]
20. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
Brenner AJ; Aldaz CM
Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]